Allergy released the results from the latest clinical study, which assessed the response from 371 patients.
The phase II trial revealed a statistically significant dose-response relationship from the groups receiving the medication, with Llobet noting the company has received “very strong top –line data”.
It means the company is still on track to start the Phase III study in early 2017, and Llobet
http://www.4-traders.com/ALLERGY-THERAPEUTICS-PLC-4004878/
Allergy Therapeutics
CEO of Allergy Therapeutics (LON:AGY) comments on positive phase II data#pharmaceutical #pharma #allergysolution pic.twitter.com/ddqE0U1EvU
— Five Minute Pitch TV (@fiveminutepitch) May 10, 2016
Immunomic Therapeutics is MD Tech Council 2016 Life Science Co. MoCo firm game-changer in allergy vaccines! @MCEDC https://t.co/qo4jjOlGSb
— Judy Stephenson (@MCSmallBizNav) June 3, 2016
Allergy Therapeutics director on novel dust mite allergy treatment https://t.co/ownC0VuNnw https://t.co/yX8BAmfrUr
— Michael Schmitt (@michaelbloggs) June 2, 2016
Global Allergy Diagnostics And Therapeutics Market Size, Share, Analysis, Outlook and… https://t.co/U0vlXbFrki
— BizPR (@bizpressrelease) May 30, 2016
#Gamblingnews Allergy Therapeutics plc (AGY) Stock Rating Reaffirmed by Panmure Gordon https://t.co/ou6PL0ShKf
— All Gambling News (@pokerporn) May 30, 2016